IMMUNOPHENOTYPIC PROFILE OF MALIGNANT B-LYMPHOCYTES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OF DIFFERENT MORPHOLOGICAL VARIANTS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-3-2022-g.10776Keywords:
CD150, CD180, CD38, immunophenotype, mixed cell type chronic lymphocytic leukemia, ypical chronic lymphocytic leukemiaAbstract
Aim: to determine the features of the expression of immunophenotypic markers on malignant B cells of typical and mixed cell type chronic lymphocytic leukemia. Object and methods: the studies were conducted on peripheral blood mononuclear cells separated by Lymphoprep gradient centrifugation of 32 patients with newly diagnosed and untreated chronic lymphocytic leukemia (CLL) (12 women and 20 men with the average age of 65.4 ± 1.7 years). The profile of the expression of surface antigens on leukemic B-cells of CLL cases was studied by flow cytometry. Results: it was determined that CLL of mixed cell type (CLL/PL), which has a worse prognosis than typical CLL (B-CLL), is characterized by a higher frequency of CD38-positive and CD150- and CD180-negative cases. The following differences in the immunophenotypic profile of malignant B cells of patients with CLL were revealed: among patients with CLL/PL, the mean percentage of positive B-cells for CD5, CD11c, CD22 is significantly higher, and CD23, CD40, CD150, and CD180 is lower than in В-CLL. In addition, a higher expression level of CD5, CD22 and a lower expression level of CD20 and CD23 are characteristics of leukemic B cells of patients with CLL/PL in comparison to B-CLL (p <0.05). Conclusion: B-CLL and CLL/PL differ in the expression profile of some immunophenotypic markers, the determination of which is expedient for prediction of the course of the disease and choosing the most effective therapy at the diagnostic stage.
References
Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. French-American-British (FAB) Cooperative Group. J Clin Patol 1989; 42 (6): 567–84. doi: 10.1136/jcp.42.6.567.
Muller-Hemerlink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukemia. World health organization classification of tumors IARC pathology and genetics of tumors of haematopoetic and lymphoid tissues. Lion: IARC Press, 2001: 127–30.
Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8 (10): 1640–5.
Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108 (4): 378–82. doi: 10.1093/ajcp/108.4.378.
Urbaniak M, Iskierka-Jażdżewska E, Majchrzak A. Atypical immunophenotype of chronic lymphocytic leukemia. Acta Haematologica Polonica 2022; 53 (1): 48–52. doi: 10.5603/AHP.a2021.0096.
Melo JV, Catovsky D, Gregory WM, et al. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 1987; 65 (1): 23–9. doi: 10.1111/j.1365-2141.1987.tb06130.x.
Oscier D, Else M, Matutes E, et al. The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol 2016; 174 (5): 767–75. doi: 10.1111/bjh.14132.
Lens D, Dyer MJ, Garcia-Marco JM, et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997; 99 (4): 848–57. doi: 10.1046/j.1365-2141.1997.4723278.x.
Bologna C, Buonincontri R, Serra S, et al. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. J Clin Invest 2016; 126 (1): 181–94. doi: 10.1172/JCI83013.
Gordiienko I, Shlapatska L, Kholodniuk V, et al. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. PLoS One 2017; 12 (10): e0185940. doi: 10.1371/journal.pone.0185940.
Li Y, Tong X, Huang L, et al. A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. Cancer Medicine 2021; 10: 4387–4396. doi: 10.1002/cam4.3983.
Ozdemir ZN, Falay M, Parmaksiz A, et al. A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry. Hematol Transfus Cell Ther 2021: S2531-1379 (21)01317-1. doi: 10.1016/j.htct.2021.08.012.
Gordiienko I, Shlapatska L, Kholodniuk V, et al. CD150 and CD180 are involved in regulation of transcription factors expression in chronic lymphocytic leukemia cells. Exp Oncol 2017; 39 (4): 291–8.
Giudice V, Serio B, Bertolini A, et al. Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia. Eur J Haematol 2022; 109 (5): 483–93. doi: 10.1111/ejh.13833.
Gluzman DF, Sklyarenko LM, Ivanyvskaya TS, et al. Chronic lymphocytic leukemia: laboratory diagnosis and prognostic criterions. Oncology 2014; 16 (3): 171–6. (in Ukrainian).
Vilpo G, Karhu R, Tobin G, et al. More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia. Genes Chromosomes Cancer 2003; 37 (4): 417–20. doi: 10.1002/gcc.10227.
Schilhabel A, Walte P, Cramer P, et al. CD20 expression as a possible novel prognostic marker in CLL: application of EuroFlow standardization technique and normalization procedures in Flow cytometric expression analysis. Cancers (Basel) 2022; 14 (19): 4917. doi: 10.3390/cancers14194917.
Okaly GV, Nargund AR, Venkataswamy E, et al. Chronic lymphoproliferative disorders at an Indian tertiary cancer centre — the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia. J Clin Diagn Res 2013; 7 (7): 1366–71. doi: 10.7860/JCDR/2013/5088.3130.
Robak P, Robak T. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. Expert Opin Biol Ther 2022; 17: 1–15. doi: 10.1080/14712598.2022.2145881.
Olejniczak SH, Stewart CC, Donohue K, et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 2006; 35 (1): 93–114. doi: 10.1080/08820130500496878.
Pozzo F, Bittolo T, Arruga F, et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia 2016; 30 (1): 182–9. doi: 10.1038/leu.2015.182.
Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008; 141 (1): 36–40. doi: 10.1111/j.1365-2141.2008.07012.x.
Balakrishna J, Basumallik N, Matulonis R, et al. Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. Leuk Lymphoma 2021; 62 (8): 1828–39. doi:10.1080/10428194.2021.1894641.
Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92 (2): 382–8. doi: 10.1046/j.1365-2141.1996.d01-1478.x.
Delgado R, Kielbassa K, Burg J, et al. Co-stimulatory versus cell death aspects of agonistic CD40 monoclonal antibody selicrelumab in chronic lymphocytic leukemia. Cancers 2021, 13 (12): 3084. doi: 10.3390/cancers13123084.
Shcherbina V, Gordiienko I, Shlapatska L, et al. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell receptors. Exp Oncology 2020; 42 (1): 16–24. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-1.14093.
Scielzo C, Apollonio B, Scarfo L, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011; 25 (11): 1760–7. doi: 10.1038/leu.2011.149.
Payandeh Z, Noori E, Khalesi B, et al. Anti-CD37 targeted immunotherapy of B-Cell malignancies. Biotechnol Lett. 2018; 40 (11-12): 1459–66. doi: 10.1007/s10529-018-2612-6
Li XL, Zhang CX. New emerging therapies in the management of chronic lymphocytic leukemia. Oncol Lett 2016; 12 (5): 3051–4. doi: 10.3892/ol.2016.5108.
Robak T, Robak P. Аnti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther 2014; 14 (5): 651–61. doi: 10.1517/14712598.2014.890182.
Kraus TS, Sillings CN, Saxe DF, et al. The role of CD11c expression in the diagnosis of mantle cell lymphoma. Am J Clin Pathol 2010; 134 (2): 271–7. doi: 10.1309/AJCPOGCI3DAXVUMI.
Eistere W, Hilbe W, Stauder R, et al. An aggressive subtype of B-CLL is characterized by strong CD44 expression and lack of CD11c. Br J Haematol 1996; 93 (3): 661–9. doi: 10.1046/j.1365-2141.1996.d01-1704.x.
Zucchetto A, Vaisitti T, Benedetti D, et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia. 2012; 26 (6): 1301–12. doi: 10.1038/leu.2011.369.
Deaglio S, Vaisitti T, Zucchetto A, et al. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol 2010; 20 (6): 416–23. doi: 10.1016/j.semcancer.2010.08.003.
Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukemia. Br J Haematol 2002; 116 (1): 142–50. doi: 10.1046/j.0007-1048.2001.3205.x.
Frater J, McCarron K, Hammel G, et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol 2001; 116 (5): 655–64. doi: 10.1309/7Q1J-1AA8-DU4Q-PVLQ.
Porakishvili N, Kulikova N, Jewell AP, et al. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005; 131 (3): 313–9. doi: 10.1111/j.1365-2141.2005.05775.x.
Porakishvili N, Memon A, Vispute K, et al. CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells. Br J Haematol 2011; 153 (4): 486–98. doi: 10.1111/j.1365-2141.2011.08605.x.
Tomomatsu J, Isobe Y, Oshimi K, et al. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma 2010; 51 (12): 2230–9. doi: 10.3109/10428194.2010.527403.
Jang M-A, Yoo E-H, Kim K, et al. Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. Int J Hematol 2013; 97 (3): 403–8. doi: 10.1007/s12185-013-1286-z.
Skarzynksi M, Niemann CU, Lee SY, et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res 2016; 22 (1): 86–95. doi: 10.1158/1078-0432.CCR-15-1304.
Bojarczuk K, Siernicka M, Dwojak M, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 2014; 28 (5): 1163–7. doi: 10.1038/leu.2014.12.
